Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Aurora, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 241–252 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting Phase 3 Interventional

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

NCT07867080
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
59
States / cities
Scottsdale, Arizona • Encino, California • Fullerton, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Zilovertamab vedotin, Pembrolizumab, MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mindfulness-Based Intervention for Depression and Insulin Resistance in Adolescents

NCT04992299
View directory record Official record
Conditions
Type 2 Diabetes, Depression, Insulin Resistance, Obesity, Adolescent Development
Interventions
Mindfulness-Based Intervention, Cognitive-Behavioral Therapy, Health Education
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
12 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting No phase listed Observational

Complex Aneurysm Registry - Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices

NCT06215105
View directory record Official record
Conditions
Cerebral Aneurysm, Intracranial Aneurysms
Interventions
Commercially available MicroVention Intracranial Aneurysm Treatment Devices
Device
Lead sponsor
Microvention-Terumo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Walnut Creek, California • Englewood, Colorado • Hartford, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Active, not recruiting Phase 3 Interventional

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

NCT05047172
View directory record Official record
Conditions
Intracranial Arteriosclerosis, Stroke
Interventions
Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
114
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting Phase 1 Interventional

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

NCT06854640
View directory record Official record
Conditions
Sepsis, Coagulopathy
Interventions
BAY3389934
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

NCT05506943
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions
CTX-009, Paclitaxel
Drug
Lead sponsor
Compass Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting Phase 2 Interventional

The Progressive Supranuclear Palsy Clinical Trial Platform

NCT07173803
View directory record Official record
Conditions
Progressive Supranuclear Palsy(PSP)
Interventions
AADvac1, LM11A-31
Biological · Drug
Lead sponsor
Adam Boxer
Other
Eligibility
41 Years to 86 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig (ABBV-383)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Springdale, Arkansas • Aurora, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 8:36 AM EST